CefoperazoneCAS# 62893-19-0 |
- Pefloxacin Mesylate Dihydrate
Catalog No.:BCC5089
CAS No.:149676-40-4
- Besifloxacin HCl
Catalog No.:BCC4764
CAS No.:405165-61-9
- Norfloxacin hydrochloride
Catalog No.:BCC4230
CAS No.:68077-27-0
- Pefloxacin
Catalog No.:BCC4231
CAS No.:70458-92-3
- Pefloxacin Mesylate
Catalog No.:BCC4821
CAS No.:70458-95-6
- Norfloxacin
Catalog No.:BCC4688
CAS No.:70458-96-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 62893-19-0 | SDF | Download SDF |
| PubChem ID | 44187 | Appearance | Powder |
| Formula | C25H27N9O8S2 | M.Wt | 645.66 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (154.88 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | ||
| SMILES | CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=C(C=C2)O)C(=O)NC3C4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O | ||
| Standard InChIKey | GCFBRXLSHGKWDP-XCGNWRKASA-N | ||
| Standard InChI | InChI=1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Cefoperazone is a cephalosporin antibiotic for inhibition of rMrp2-mediated [3H]E217βG uptake with IC50 of 199 μM.
Target: Antibacterial
Cefoperazone is a sterile, semisynthetic, broad-spectrum, parenteral cephalosporin antibiotic for intravenous or intramuscular administration. After intravenous administration of 2 g of Cefoperazone, levels in serum rang from 202μg/mL to 375 μg/mL depending on the period of drug administration. After intramuscular injection of 2 g of Cefoperazone, the mean peak serum level is 111 μg/mL at 1.5 hours. At 12 hours after dosing, mean serum levels are still 2 to 4 μg/mL. Cefoperazone is 90% bound to serum proteins. References: | |||||
Cefoperazone Dilution Calculator
Cefoperazone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5488 mL | 7.744 mL | 15.488 mL | 30.9761 mL | 38.7201 mL |
| 5 mM | 0.3098 mL | 1.5488 mL | 3.0976 mL | 6.1952 mL | 7.744 mL |
| 10 mM | 0.1549 mL | 0.7744 mL | 1.5488 mL | 3.0976 mL | 3.872 mL |
| 50 mM | 0.031 mL | 0.1549 mL | 0.3098 mL | 0.6195 mL | 0.7744 mL |
| 100 mM | 0.0155 mL | 0.0774 mL | 0.1549 mL | 0.3098 mL | 0.3872 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Cefoperazone is an antimicrobial agent that possesses potent LACTB (β-lactamase) inhibitory properties.
- Hecubine
Catalog No.:BCN7467
CAS No.:62874-52-6
- TP 003
Catalog No.:BCC6169
CAS No.:628690-75-5
- Senampeline B
Catalog No.:BCN2031
CAS No.:62860-52-0
- 2-Amino-6-nitrobenzothiazole
Catalog No.:BCC8544
CAS No.:6285-57-0
- Senampeline E
Catalog No.:BCN2032
CAS No.:71075-42-8
- Meglumine
Catalog No.:BCC4795
CAS No.:6284-40-8
- Jolkinol A
Catalog No.:BCN3778
CAS No.:62820-11-5
- Palmitic acid ethyl ester
Catalog No.:BCN8298
CAS No.:628-97-7
- SU14813
Catalog No.:BCC1971
CAS No.:627908-92-3
- Senampeline D
Catalog No.:BCN2033
CAS No.:62787-01-3
- Senampeline A
Catalog No.:BCN2030
CAS No.:62787-00-2
- Pterophorine
Catalog No.:BCN2118
CAS No.:62786-99-6
- Heptanal oxime
Catalog No.:BCN2267
CAS No.:629-31-2
- Procaterol hydrochloride
Catalog No.:BCC6937
CAS No.:62929-91-3
- H-D-Pro-NH2
Catalog No.:BCC3024
CAS No.:62937-45-5
- Kuwanon A
Catalog No.:BCN2944
CAS No.:62949-77-3
- Mulberrin
Catalog No.:BCN4167
CAS No.:62949-79-5
- Morusinol
Catalog No.:BCN4168
CAS No.:62949-93-3
- 6-Methoxy-4-methylcoumarin
Catalog No.:BCN6537
CAS No.:6295-35-8
- (2-Benzothiazolylthio)acetic acid
Catalog No.:BCC8387
CAS No.:6295-57-4
- Gomisin F
Catalog No.:BCN3625
CAS No.:62956-47-2
- Gomisin G
Catalog No.:BCN2269
CAS No.:62956-48-3
- Gnetucleistol D
Catalog No.:BCN3400
CAS No.:629643-26-1
- Boc-Tle-OH
Catalog No.:BCC3343
CAS No.:62965-35-9
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291.[Pubmed:28060346]
J Vis Exp. 2016 Dec 10;(118).
Clostridium difficile is an anaerobic, gram-positive, spore-forming enteric pathogen that is associated with increasing morbidity and mortality and consequently poses an urgent threat to public health. Recurrence of a C. difficile infection (CDI) after successful treatment with antibiotics is high, occurring in 20-30% of patients, thus necessitating the discovery of novel therapeutics against this pathogen. Current animal models of CDI result in high mortality rates and thus do not approximate the chronic, insidious disease manifestations seen in humans with CDI. To evaluate therapeutics against C. difficile, a mouse model approximating human disease utilizing a clinically-relevant strain is needed. This protocol outlines the Cefoperazone mouse model of CDI using a clinically-relevant and genetically-tractable strain, R20291. Techniques for clinical disease monitoring, C. difficile bacterial enumeration, toxin cytotoxicity, and histopathological changes throughout CDI in a mouse model are detailed in the protocol. Compared to other mouse models of CDI, this model is not uniformly lethal at the dose administered, allowing for the observation of a prolonged clinical course of infection concordant with the human disease. Therefore, this Cefoperazone mouse model of CDI proves a valuable experimental platform to assess the effects of novel therapeutics on the amelioration of clinical disease and on the restoration of colonization resistance against C. difficile.
Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014).[Pubmed:28341098]
Diagn Microbiol Infect Dis. 2017 Jun;88(2):177-183.
A total of 18,386 organisms, including 13,224 Enterobacteriaceae, 3536 Pseudomonas aeruginosa, 1254 Acinetobacter spp., and 372Stenotrophomonas maltophilia were collected from Western Europe (WEU; n=10,021), Eastern Europe (EEU; n=4957), and the Asia-Pacific region (APAC; n=3408 [1052 from China]) in 2013-2014 as part of the SENTRY Antimicrobial Surveillance Program and tested by a reference broth microdilution method for susceptibility against tigecycline, Cefoperazone/sulbactam, and comparator agents. Overall, 95.3% of Enterobacteriaceae were susceptible (Cefoperazone/sulbactam inhibited 94.6/83.5/91.5% of Enterobacteriaceae at
Acute localized exanthematous pustulosis caused by cefoperazone and sodium sulbactam.[Pubmed:28099605]
An Bras Dermatol. 2016 Nov-Dec;91(6):808-810.
Acute localized exanthematous pustulosis is a localized variant of acute generalized exanthematous pustulosis, which is characterized by the eruption of multiple scattered pustules following drug administration. A 72-year-old woman presented with multiple erythematous pustules on her face, which had appeared two days after using Cefoperazone and sodium sulbactam. Histopathological findings showed subcorneal pustules and mixed inflammatory cell infiltration in the dermis. The pustules resolved within about two weeks after the patient discontinued the antibiotics. This report discusses the case of a woman with a cutaneous drug reaction consistent with acute localized exanthematous pustulosis that occurred after Cefoperazone and sodium sulbactam were administered.
